Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network, University of Toronto, 399 Bathurst Street 1E-416, Toronto, Ontario, M5T 2S8, Canada.
Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada.
Clin Rheumatol. 2020 Aug;39(8):2355-2361. doi: 10.1007/s10067-020-05003-9. Epub 2020 Feb 25.
INTRODUCTION/OBJECTIVES: Intra-articular corticosteroid (IAS) injections are often used for the immediate relief of pain and inflammation in the joint of psoriatic arthritis (PsA) patients. However, studies identifying factors that predict response to the IAS injections are lacking. We aimed to assess the usefulness of serine proteinase activity measurements in PsA synovial fluid (SF) samples obtained at the time of injection in predicting clinical response.
The PsA patients with available SF samples from the knee joint were identified from the University of Toronto PsA cohort. Clinical response was defined as an absence of tenderness or swelling in the injected joint at the first post-injection visit, at either 3 or 6 months. SF proteinase activity was determined by measuring cleavage of fluorogenic tri-peptide substrates for trypsin-like (VPR-AMC and VLK-AMC) and chymotrypsin-like (AAPF-AMC) serine proteinases. Generalized estimating equation (GEE) models were used to investigate factors associated with response.
A total of 32 patients with 60 injected joints and data available for follow-up at 3 or 6 months were included in the analysis, with 25 (41.7%) injected joints resulting in clinical response. Age, sex, active joint count, systemic medications and SF serine proteinase activity at the time of injection were included as covariates. Only treatment with biologics was significantly associated with response at 3 or 6 months in the multivariate reduced model (OR 3.02, p = 0.027).
We could not demonstrate an association between SF serine proteinase activity and response to IAS injection. Biologic agents significantly improve the likelihood of achieving clinical response.
简介/目的:关节内皮质类固醇(IAS)注射常用于立即缓解银屑病关节炎(PsA)患者关节的疼痛和炎症。然而,缺乏识别预测 IAS 注射反应的因素的研究。我们旨在评估在注射时获得的 PsA 滑液(SF)样本中丝氨酸蛋白酶活性测量在预测临床反应中的有用性。
从多伦多大学 PsA 队列中确定了有膝关节 SF 样本的 PsA 患者。临床反应定义为在注射后第一次就诊时,无论是在 3 个月还是 6 个月时,注射关节无压痛或肿胀。SF 蛋白酶活性通过测量荧光三肽底物对胰蛋白酶样(VPR-AMC 和 VLK-AMC)和糜蛋白酶样(AAPF-AMC)丝氨酸蛋白酶的裂解来确定。使用广义估计方程(GEE)模型研究与反应相关的因素。
共有 32 名患者的 60 个注射关节在 3 或 6 个月时可获得随访数据,其中 25 个(41.7%)注射关节有临床反应。年龄、性别、活跃关节计数、全身药物和注射时的 SF 丝氨酸蛋白酶活性被纳入协变量。只有在多变量简化模型中,生物制剂治疗在 3 个月或 6 个月时与反应显著相关(OR 3.02,p=0.027)。
我们无法证明 SF 丝氨酸蛋白酶活性与 IAS 注射反应之间存在关联。生物制剂显著提高了实现临床反应的可能性。